This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This study sought to examine temporal trends in the clinical characteristics and inhospital occurrence of adverse outcomes of IE.Methods and ResultsUsing the Japan nationwide administrative database, we identified patients with IE in Japan from 2016 to 2021. per 100 000 population in 2016 to 2.59 in 2016 to 15.4%
Background Early prediction of heartfailure (HF) after acute myocardial infarction (AMI) is essential for personalized treatment. The primary endpoint was the occurrence of HF within 3 years after operation.
In a new study published in JACC: HeartFailure , maternal loss of a partner or child shortly before or during pregnancy was found to be associated with increased risk of heartfailure up to middle-age in the child. According to the World Heart Federation, more than 64 million people worldwide have heartfailure.
Inhibiting the function of this protein, which is linked to congestive heartfailure (CHF), could potentially lead to a therapeutic effect on the heart.1,2 Inhibiting the function of this protein, which is linked to congestive heartfailure (CHF), could potentially lead to a therapeutic effect on the heart.1,2
(AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG , announced that it is initiating GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase 2 trial of AB-1002 (also known as NAN-101 ) for the treatment of congestive heartfailure (CHF). Heartfailure. 2016:25:2. [5]
Treatment options for heartfailure with preserved ejection fraction have historically been limited. In a 2016 review of this condition in the Journal, treatment recommendations focused on diuretics, exercise training, and management of coexisting conditions.1
Statins are one of the most-prescribed drug classes in the world, but there’s still little data on their heartfailure benefits, especially for HFpEF patients. The two major RCTs evaluating statins as a heartfailure treatment (CORONA and GISSI-HF) didn’t show significant benefits, although they mainly focused on HFrEF patients.
Edwards anticipates FDA approval of the JenaValve Trilogy Heart Valve System in late 2025, which will represent the first approved therapy for patients suffering from AR. Building on an investment made in 2016, Edwards has exercised its option to acquire Endotronix , a leader in heartfailure (HF) management solutions.
Journal of the American Heart Association, Volume 13, Issue 24 , December 17, 2024. EAT volume and extracellular volume were calculated using cardiovascular magnetic resonance. The main outcome was the composite of allcause mortality and first HF hospitalization.
Data on major cardiovascular events (MACE; mortality, myocardial infarction, stroke, heartfailure) through December 2021 were obtained from national registries. The use of cardioprotective GLD increased rapidly in recent years (2016–2021; 7–47%) and was more common in younger patients (66 vs. 68 years) and men (72.9%
Diagrammatic illustration of trends of incident heartfailure diagnosis and diagnostic testing in the US from 2016 to 2019 stratified by inpatient and outpatient setting. However, real-world utilization of these diagnostic tests in the US is not known.
Aims We investigated the incremental advantage in terms of N-terminal pro-B-type natriuretic peptide (NT-proBNP) reduction in patients affected by heartfailure with reduced ejection fraction (HFrEF) treated with sacubitril/valsartan (S/V) and mineralocorticoid receptor antagonists (MRA) versus patients treated with S/V only.
Data were prospectively gathered from individuals aged 1 to under 18 years participating in the European Society of Cardiology EURObservational Research Programme Cardiomyopathy and Myocarditis long-term registry spanning from June 2014 to December 2016. Familial disease was identified in 47.3% (n = 253) of patients. months (IQR: 11.3–15.3),
CHD admissions remained stable from 2016 to 2020. Patients without CHD were older (mean age 71.5 years) than those with DV-CHD (mean age 59.8 years) and SV-CHD (mean age 17.9 Non-CHD patients had shorter stays (mean 5.8 days), and lower total charges.
Today’s video is on the subject of heartfailure. Heartfailure is a chronic clinical syndrome characterised by the inability of the heart to pump out enough blood to meet the body’s requirements. Anything that affects the heart in a bad way may in its severest form lead to heartfailure.
Circulation: HeartFailure, Ahead of Print. Centers performing at least 1 heart transplant or left ventricular assist device were classified as ATCs. Patient characteristics, outcomes, and procedural volume were compared among 3 cohorts: admissions to non-ATCs, admissions to ATCs, and transfers to ATCs.
Circulation: HeartFailure, Ahead of Print. Background:Current prevalence estimates of heartfailure (HF) are primarily based on self-report or HF hospitalizations. Results:Median age was 73 (25th–75th percentile 67–81) years, 53.2% were female, 25.6% were Black, 12.8% were Chinese, and 40.0% were White.
Apparent treatment-resistant hypertension is defined as the need to take three or more types of anti-high blood pressure medication daily and is associated with an increased risk for stroke , coronary heart disease , heartfailure , and all-cause mortality. Over a period of 9.5 of white adults.
As heartfailure with preserved ejection fraction (HFpEF) comprises half of all heartfailure cases, understanding its management and effect on outcomes is crucial. Background:Opioid use has increased significantly in the past few decades, impacting cardiac and non-cardiac patients.
Methods Using the Korean National Health Insurance Service database, we included patients aged ≥75 years with new-onset AF from January 2009 to December 2016 ( n = 41,315). Objective To evaluate the impact of combined ERC and HLS on the risk of stroke in elderly patients with new-onset AF.
In a recent study published in Circulation: HeartFailure , researchers analyzed a large group of individuals with various cardiopulmonary diseases who had undergone right heart catheterization. year follow-up, those with right ventricular dysfunction faced an increased risk of mortality and heartfailure hospitalization.
Background:Tricuspid regurgitation (TR) is a common occurrence in patients with heartfailure (HF), and its role in disease progression has gained attention in recent years. Circulation, Volume 150, Issue Suppl_1 , Page A4142159-A4142159, November 12, 2024. and I07.1.
Background:Tricuspid regurgitation (TR) is a common occurrence in patients with heartfailure (HF), and its role in disease progression has gained attention in recent years. Circulation, Volume 150, Issue Suppl_1 , Page A4140781-A4140781, November 12, 2024. and I07.1.
Johnson & Johnson expanded deeper into heartfailure and interventional cardiology, acquiring interatrial shunt-maker V-Wave for $600M upfront and up to $1.7B The two companies are already well-acquainted, as J&J led V-Wave’s 2016 Series B and was involved in subsequent rounds. with certain milestones.
IntroductionCardiomyopathy (CM) is a diverse pathology defined by both structural and functional changes in the heart. The National Inpatient Sample (NIS) database from 2016‐2019 for patients with a principal diagnosis of AIS using the ICD‐10 code I63 was queried. AIS patients with CM and HF were compared to those without.
Abstract Background and Aims Patients who experience hospitalizations due to heartfailure (HF) face a significant risk of readmission and mortality. Methods We studied all adults admitted for a first HF hospitalization from 2016 to 2020 in France's Grand Est region. Results Among 67 476 admitted patients (mean age 80.3 ± 11.3 years,
This study evaluates the outcomes in patients admitted for HF with and without hyperkalemia.Methods:We used the Nationwide Readmissions Database (NRD) from 2016-2019, extracting adult patients with a primary diagnosis of HF who were admitted between January and November of each year. Survey procedures were applied using SAS 9.4.Results:We
years; 67% men, 33% women) with severely symptomatic HOCM who underwent PIMSRA from October 2016 to September 2017 were included. Malignant ventricular arrhythmia and heartfailure events were not observed. Methods 27 patients (age: 44.3±15.5 Trial registration number NCT02888132.
The primary outcome was the first occurrence of major cardiovascular events defined as a composite of hospitalisation for acute coronary syndrome (non-fatal myocardial infarction and unstable angina), fatal myocardial infarction, non-fatal and fatal stroke, sudden death and heartfailure.
Among 475 patients with cardiac sarcoidosis, 119 (25.1%) were isolated cardiac sarcoidosis (iCS) based on the 2016 Japanese Circulation Society criteria. iCS was diagnosed according to the 2016 Japanese Circulation Society (JCS) guidelines. Among 475 patients with CS (mean age, 62.0 ± 10.9 years; During a median follow-up of 42.3
Circulation: HeartFailure, Volume 16, Issue 11 , Page e010524, November 1, 2023. The role of obesity in RV dysfunction and adverse outcomes is unclear.METHODS:We examined patients undergoing right heart catheterization between 2005 and 2016 in a hospital-based cohort. P<0.001). Over median of 7.3
Gorter TM, van Veldhuisen DJ, Bauersachs et al Right heart dysfunction and failure in heartfailure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the HeartFailure Association of the European Society of Cardiology. Eur J Heart Fail. 2018 Jan;20(1):16-37.
years]) admitted to the China Chest Pain Center Database between 2016 and 2021. Hierarchical clustering of 15 medical conditions was performed to derive multimorbidity patterns. The primary outcome was a composite of inhospital adverse events.
About AFib, AI and Clinical Trials from HRS 2024 The American Heart Association defines AFib as a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heartfailure, and other heart-related complications. 1 Approximately 33 million patients worldwide are living with AFib.
There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heartfailure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] Is the obesity paradox a real phenomenon?
from 2016‐2019 and secondary diagnosis of T2DM. Data was weighted to allow for representative nationwide estimates.ResultsWe identified 426,549 patients who were admitted with a primary diagnosis of TIA between 2016 and 2019. The primary diagnosis of the readmission was used to identify the etiology of readmission.
The multivariate analysis also revealed that age less than a year, HCM compared to DCM, history of heartfailure, pre-procedural inotropic support, and non-elective procedure were associated with increased rate of MAE. The leading cause of mortality was heartfailure in 51% of deceased patients. were females.
We aimed to examine the incidence of and risk factors for cardiotoxicity in a racially and ethnically diverse cohort with cancer treated with anthracyclines.MethodsWe included consecutive adult patients who underwent anthracyclinebased chemotherapy from 2016 to 2019 for any type of cancer. ResultsA total of 743 individuals were included (28.0%
x) from 2016‐2019. The rate of 30‐day readmission was overall stable (7.34% in 2016 and 7.70% in 2019; p=0.42), but the 90‐day readmission rate slightly increased from 11.69% in 2016 to 12.47% in 2019 (p=0.04). ConclusionThe annual rate of 90‐day readmission, but not 30‐day readmission, increased from 2016 to 2019.
SCD is the leading cause of mortality in heartfailure. N Engl J Med 2016; 375:1221-1230) Why ICD doesn’t work well in NDCM ? Bardy GH, Lee KL, Mark DB, Poole JE, Sudden Cardiac Death in HeartFailure Trial (SCD-HeFT) Investigators. 2016 Sep 29;375(13):1221-30. N Engl J Med. 2005 Jan 20;352(3):225-37.
x) from 2016‐2019 using the Nationwide Readmission Database (NRD). Data was weighted to allow for representative nationwide estimates.ResultsA total of 260,854 patients were admitted with a primary diagnosis of ICH between 2016‐2019. The mean age of the cohort was 68.49 years, with 52.6% being male.
We then identified patients receiving GLP1RA or SGLT2i and evaluated trends over time.Results:4131 patients were identified of which 2045 (49.4%) had a diagnosis of diabetes. Of these patients 60/2045 (2.9%) were on GLP1RA while 35/2045 (1.7%) were on SGTLi for total of 4.6%.
Annual follow-up interviews were conducted from inception until 2016 to determine outcomes of interest. Hospital records were reviewed and incident MACE, defined as the composite of incident stroke, myocardial infarction, or heartfailure, was adjudicated using standard criteria. for all; IRR 0.44, 95% CI 0.23 in females).Conclusion:Among
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content